Search

Your search keyword '"Hohenstein, Bernd"' showing total 505 results

Search Constraints

Start Over You searched for: Author "Hohenstein, Bernd" Remove constraint Author: "Hohenstein, Bernd"
505 results on '"Hohenstein, Bernd"'

Search Results

4. SGLT2-Inhibition in Patients With Alport Syndrome

6. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

7. SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality)

8. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

9. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

10. Overexpression of alanine-glyoxylate aminotransferase 2 protects from asymmetric dimethylarginine-induced endothelial dysfunction and aortic remodeling

11. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy

12. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

15. Adressen

18. A microphysiological system to investigate the pressure dependent filtration at an artificial glomerular kidney barrier

19. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

20. Toward an international consensus—Integrating lipoprotein apheresis and new lipid-lowering drugs

21. Post COVID and Apheresis – Where are we Standing?

23. Contributors

25. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

27. SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality)

28. 3D printing – a key technology for tailored biomedical cell culture lab ware

33. Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort

35. The German Lipoprotein Apheresis Registry—Summary of the ninth annual report.

36. Adressen

39. Clinical course and predictive risk factors for fatal outcome of SARS-CoV-2 infection in patients with chronic kidney disease

40. Solid organ transplantation is not a risk factor for COVID-19 disease outcome

41. Enhanced progenitor cell recruitment and endothelial repair after selective endothelial injury of the mouse kidney

44. Thrombospondin-2 therapy ameliorates experimental glomerulonephritis via inhibition of cell proliferation, inflammation, and TGF-[beta] activation

45. Overexpression of Alanine-glyoxylate aminotransferase 2 Protects from Asymmetric Dimethylarginine-induced Endothelial Dysfunction and Aortic Remodeling

47. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition

49. Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis

50. Isolated FSH Deficiency

Catalog

Books, media, physical & digital resources